Use of interferon in the treatment of ovarian cancer as a single agent and in combination with cytotoxic drugs
β Scribed by Charles E. Welander
- Publisher
- John Wiley and Sons
- Year
- 1987
- Tongue
- English
- Weight
- 311 KB
- Volume
- 59
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## BACKGROUND. The authors combined cisplatin and carboplatin together with cyclophosphamide to maximize platinum dose intensity in patients with advanced epithelial ovarian cancer (AOC). ## METHODS. The authors treated 26 consecutive, newly diagnosed patients with International Federation of G
Background. Chemotherapy has dramatically improved the rates of cure and survival of patients with localized and metastatic osteosarcoma. Nonetheless, the number of chemotherapeutic agents active against osteosarcoma is limited to doxorubicin, cisplatin, high-dose methotrexate, and ifosfamide. Carbo
## Background: The objective of the current study was to evaluate the response rate, survival, and toxicity of treatment with cisplatin and high dose intravenous continuous infusion interleukin-2 (il-2) with or without interferon-alpha-2a (ifn) in patients with metastatic melanoma. ## Methods: On